Ontology highlight
ABSTRACT:
SUBMITTER: Ezell SA
PROVIDER: S-EPMC4148116 | biostudies-literature | 2014 Jul
REPOSITORIES: biostudies-literature
Ezell Scott A SA Mayo Michele M Bihani Teeru T Tepsuporn Suprawee S Wang Suping S Passino Melissa M Grosskurth Shaun E SE Collins Mike M Parmentier Julie J Reimer Corinne C Byth Kate F KF
Oncotarget 20140701 13
Diffuse large B cell lymphoma is generally treated by chemotherapy and there is an unmet medical need for novel targeted therapies or combination therapies. Using in vitro screening, we have identified the combination of ibrutinib, an inhibitor of the tyrosine kinase BTK, and AZD2014, an mTOR catalytic inhibitor, as being highly synergistic in killing ABC-subtype DLBCL cell lines. Simultaneous inhibition of BTK and mTOR causes apoptosis both in vitro and in vivo and results in tumor regression i ...[more]